1. Microbiology

Category Archives: Microbiology

Antimicrobial Test Laboratories Emerges as Leading Provider of Virus Testing Services

Posted on by

Antimicrobial Test Laboratories - a contract microbiology lab founded in 2006 by microbiologist Dr. Benjamin Tanner - has experienced rapid growth of its virus testing services to match its expanding reputation for rapid study turnarounds, reproducible results, and attentive customer service.

Round Rock, TX (PRWEB) April 10, 2013

Virus testing is unique within the laboratory because the presence of viruses before and after treatment with antimicrobials is signaled to ATL scientists by infection and damage to mammalian host cells, rather than growth of bacterial or fungal colonies on agar plates.

ATL has invested considerable resources to build and maintain the sterile cell cultures needed to propagate and detect viruses for antimicrobial efficacy studies, said ATL president and founder Benjamin Tanner, Ph.D. It requires scientific focus and expertise to conduct virological assays in a consistent, reproducible fashion.

ATL's virology/cell culture unit is directed by Dr. Luisa Ikner, a microbiologist with several peer-reviewed scientific publications and years of virology experience. The laboratory's 15,000+ square foot state-of-the-art facility in Round Rock, near Austin, Texas accommodates the growing demand for its virus testing, and enables it to perform fully-compliant Good Laboratory Practice (GLP) antimicrobial testing for EPA and FDA.

It has been rewarding for me to see the companies that rely on Antimicrobial Test Laboratories for bacterial and fungal testing put their products to the test against important viral pathogens such as influenza A virus, rhinovirus, and the EPA-mandated human norovirus surrogate, feline calicivirus, Dr. Ikner added.

ATL benefits from a highly-qualified staff - many of them authors of, or past participants in, peer-reviewed scientific research including:

ATLs Virucidal Efficacy Test Methods and Services Include:

Benjamin Tanner, PhD Antimicrobial Test Laboratories 512-310-8378 Email Information

Read the original post:
Antimicrobial Test Laboratories Emerges as Leading Provider of Virus Testing Services

PSI Announces Experts to Present at 23rd European Congress of Clinical Microbiology & Infectious Diseases

Posted on by

ZUG, Switzerland--(BUSINESS WIRE)--

PSI CRO, a full-service contract research organization, continues research on differing strains of bacteria in various countries. It is important to know which pathogens and patterns of antibacterial resistance can be found in any particular country when conducting multi-national clinical trials of new antibacterial medicines. Currently, there is a lack of this data for some countries, e.g. for Central and Eastern Europe (CEE). Therefore, at the initiative of the Head, Medical Affairs at PSI, Maxim Belotserkovsky, MD, PhD, and in collaboration with the Russian National Institute of Antibacterial Chemotherapy, a surveillance program aimed at studying typical pathogens and antibacterial resistance patterns in CEE countries was instituted 5 years ago. The next report on this continuing program, Isolation rate and patterns of pathogens isolated from hospitalized patients with community-acquired pneumonia (CAP) in clinical trialswill be presented as a poster at theECCMID meetingApril 27-30 in Berlin.

About PSI CRO AG:PSIis a privately-held, full-service contract research organization (CRO), operating globally. PSI positions itself as a no-nonsense CRO capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSIsglobal reachsupports the operations of clinical trials across multiple countries and continents. PSI has exceptionally high repeat and referral business rates that are indicative of their commitment to be the best CRO in the world as measured by their clients and employees. Global headquarters are located in Zug, Switzerland at 113a Baarerstrasse 6300.

Read more:
PSI Announces Experts to Present at 23rd European Congress of Clinical Microbiology & Infectious Diseases

Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biom̩dicale! РVideo

Posted on by


Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biomédicale!
Présentation de la licence pro TCIBB, réalisée par la promo TCIBB 2012-2013. Pour tout renseignement : caroline.norez@univ-poitiers.fr.

By: Caroline Norez

Go here to read the rest:
Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biomédicale! - Video

CML HealthCare Inc. to Install North America’s First and World’s Largest Fully Automated BD Kiestraâ„¢ Microbiology …

Posted on by

MISSISSAUGA, Ontario, April 8, 2013 /PRNewswire/ --CML HealthCare Inc. (CLC.TO) (the "Company" or "CML"), a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, and BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced an agreement for CML to install two BD Kiestra Total Laboratory Automation ("TLA") systems. This fully automated microbiology system will be installed at CML's central laboratory by the third quarter of 2013. The BD Kiestra TLA system is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results.

"We are very excited to be the first laboratory services provider in North America to be installing the BD Kiestra TLA system. With our central laboratory processing approximately three million microbiology tests annually, this installation will be the largest in the world for the BD Kiestra TLA system," said Thomas Wellner, President and CEO of CML. "The implementation of the BD Kiestra TLA system will allow CML to increase our capacity, reduce result turnaround times, and contribute to the growth of our core laboratory business. It will provide us with a significant competitive advantage and support a key pillar of our growth strategy which is to establish innovative hospital and other partnerships."

BD Kiestra TLA system automates the manual processes associated with inoculating and incubating microbiology specimens, and uses digital imaging of the inoculated specimens to shorten the time to detect bacterial growth. The increased efficiency, and quality improvements associated with automation allow for faster delivery of more accurate results to provide optimal patient care. In addition, laboratory staff is able to devote more time to analytical and value-added tasks.

"BD is proud to be working with CML HealthCare Inc., one of Canada's largest and most forward-looking laboratory services providers," said Tom Polen, President, BD Diagnostics - Diagnostic Systems. "Rapid diagnosis and treatment of infections is critical; however, many of the traditional testing protocols take two or three days to generate an actionable result.Using the BD Kiestra TLA system, integrated with other rapid diagnostic technologies, CMLwill be a pioneer in implementing technology that can often reduce those times significantly. We expect this to enable clinicians to provide patients with the most effective treatment earlier thus improving the standard of care and avoiding unnecessary healthcare costs."

The BD Kiestra TLA system currently has an installation base of instruments at public hospitals, universities, and privately owned laboratories in more than eleven countries worldwide since its introduction in 2006.

About CML HealthCare Inc.

Based in Mississauga, Ontario, CML HealthCare Inc. is a leading community-based, medical diagnostic services provider in Canada operating 114 Client C.A.R.E. Centres in Ontario, 84 imaging centres in Ontario and British Columbia, and a reference laboratory in Ontario focused on specialized coagulation testing and equipment calibration for international customers. CML is publicly-traded on the Toronto Stock Exchange under the symbol "CLC" and has approximately 89.8 million common shares outstanding. For more information, please visit http://www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

For more information, please contact:

Read the original here:
CML HealthCare Inc. to Install North America's First and World's Largest Fully Automated BD Kiestraâ„¢ Microbiology ...

CML HealthCare Inc. to Install North America’s First and World’s Largest Fully Automated BD Kiestra(TM) Microbiology …

Posted on by

MISSISSAUGA, ONTARIO--(Marketwired - Apr 8, 2013) - CML HealthCare Inc. (CLC.TO) (the "Company" or "CML"), a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, and BD (Becton, Dickinson and Company) ("BD"), a leading global medical technology company, today announced an agreement for CML to install two BD Kiestra Total Laboratory Automation ("TLA") systems. This fully automated microbiology system will be installed at CML's central laboratory by the third quarter of 2013. The BD Kiestra TLA system is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results.

"We are very excited to be the first laboratory services provider in North America to be installing the BD Kiestra Total Laboratory Automation system. With our central laboratory processing approximately three million microbiology tests annually, this installation will be the largest in the world for the BD Kiestra TLA system," said Thomas Wellner, President and CEO of CML. "The implementation of the BD Kiestra TLA system will allow CML to increase our capacity, reduce result turnaround times, and contribute to the growth of our core laboratory business. It will provide us with a significant competitive advantage and support a key pillar of our growth strategy which is to establish innovative hospital and other partnerships."

BD Kiestra TLA system automates the manual processes associated with inoculating and incubating microbiology specimens, and uses digital imaging of the inoculated specimens to shorten the time to detect bacterial growth. The increased efficiency, and quality improvements associated with automation allow for faster delivery of more accurate results to provide optimal patient care. In addition, laboratory staff is able to devote more time to analytical and value-added tasks.

"BD is proud to be working with CML HealthCare Inc., one of Canada's largest and most forward looking laboratory services provider," said Tom Polen, President BD Diagnostics - Diagnostic Systems. "Rapid diagnosis and treatment of infections is critical; however, many of the traditional testing protocols take two or three days to generate an actionable result. Using the BD Kiestra TLA system, integrated with other rapid diagnostic technologies, CML will be a pioneer in implementing technology that can often reduce those times significantly. We expect this to enable clinicians to provide patients with the most effective treatment earlier - thus improving the standard of care and avoiding unnecessary healthcare costs."

The BD Kiestra TLA System currently has an installation base of instruments at public hospitals, universities, and privately owned laboratories in more than eleven countries worldwide since its introduction in 2006.

About CML HealthCare Inc.

Based in Mississauga, Ontario, CML HealthCare Inc. is a leading community-based, medical diagnostic services provider in Canada operating 114 Client C.A.R.E. Centres in Ontario, 84 imaging centres in Ontario and British Columbia, and a reference laboratory in Ontario focused on specialized coagulation testing and equipment calibration for international customers. CML is publicly-traded on the Toronto Stock Exchange under the symbol "CLC" and has approximately 89.8 million common shares outstanding. For more information, please visit http://www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

Visit link:
CML HealthCare Inc. to Install North America's First and World's Largest Fully Automated BD Kiestra(TM) Microbiology ...

New mouse viruses could aid hepatitis research

Posted on by

Public release date: 9-Apr-2013 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Newly discovered mouse viruses could pave the way for future progress in hepatitis research, enabling scientists to study human disease and vaccines in the ultimate lab animal. In a study to be published in mBio, the online open-access journal of the American Society for Microbiology, scientists describe their search for viruses related to the human hepatitis C virus (HCV) and human pegiviruses (HPgV) in frozen stocks of wild mice. The discovery of several new species of hepaciviruses and pegiviruses that are closely related to human viruses suggests they might be used to study these diseases and potential vaccines in mice, without the need for human volunteers.

About 2% of the population is infected with the hepatitis C virus and 5% is infected with human pegiviruses, but it's been difficult to study new drugs or develop vaccines against these infections because the human strains do not infect animals that can be studied in the lab. Lead author Amit Kapoor of Columbia University says it surprised him to find similar viruses in mice.

"People have been waiting for decades to find something like this. It was shocking for me to see that the viruses are there and there are so many of them," says Kapoor.

Kapoor and his colleagues screened an archive of more than 400 frozen rodents, mostly deer mice, for viruses related to the human hepatitis C virus and human pegiviruses. The search turned up a number of candidates, and they selected two for complete genome sequencing: a rodent hepacivirus (RHV) found in deer mice and a rodent pegivirus (RPgV) found in a white-throated woodrat. Sequencing confirmed that the viruses are very closely related to human strains but they represent several novel species in the Hepacivirus and Pegivirus genera within the family Flaviviridae.

These rodent viruses have genes, proteins, and translational elements that closely mirror those found in human hepaciviruses and pegiviruses, suggesting they have great potential for use in the lab. Animal models of hepatitis would help scientists explore the ways these viruses causes disease and aid in the design of treatments and vaccines. Human pegiviruses, on the other hand, have unknown effects, so studying how they work in rodents could well point the way to what they might do in the human body and why so many people are infected.

Kapoor's lab is now focused on exploring the biology of these viruses. "We are trying to infect deer mice, to study biological properties of these hepatitis C-like viruses," says Kapoor. "And if we find one of these viruses is hepatotrophic [having an attraction to the liver] and causes disease similar to hepatitis C, that would be a big step forward in understanding hepatitis C-induced pathology in humans."

###

mBio is an open access online journal published by the American Society for Microbiology to make microbiology research broadly accessible. The focus of the journal is on rapid publication of cutting-edge research spanning the entire spectrum of microbiology and related fields. It can be found online at http://mbio.asm.org.

More here:
New mouse viruses could aid hepatitis research

2013 Polar and Alpine Microbiology Conference

Posted on by

Registration and abstract submission deadline: June 1, 2013

The 5th International Conference on Polar and Alpine Microbiology (PAM5) will be held in Big Sky, Montana (USA) from 8-12 September 2013. This meeting will be a continuation of the highly successful meetings previously held in Rovaniemi, Finland (2004), Innsbruck, Austria (2006), Banff, Canada (2008) and Ljubljana, Slovenia (2011), which brought together leading international researchers and students in this field. The objectives of the Big Sky meeting will again be to bring together scientists, students and professionals to discuss all aspects of cold-adapted microorganisms and the roles they play in polar and alpine environments, to address recent developments, and to exchange ideas and experiences on an international scale. The conference will provide a multi-disciplinary forum to explore emerging areas in the field and as always, will have a wealth of opportunities for the exchange of ideas and building of collaborations.

For more information visit: http://polaralpinemicrobiology2013.montana.edu/

Please follow SpaceRef on Twitter and Like us on Facebook.

Here is the original post:
2013 Polar and Alpine Microbiology Conference

Nelson Laboratories to Conduct Pharmaceutical Microbiology Seminar

Posted on by

SALT LAKE CITY, April 3, 2013 /PRNewswire/ --Nelson Laboratories (www.nelsonlabs.com) will give pharmaceutical industry professionals direct access to its FDA trend experts during the "The Science of Pharmaceutical Microbiology Seminar" on May 16, 2013 in San Diego, Calif.

(Logo: http://photos.prnewswire.com/prnh/20120727/LA47745LOGO)

"We created this seminar to impart our industry knowledge on microbial control and aseptic processing to pharmaceutical industry representatives," said Jackson Adams, Pharmaceutical Account Manager. "The benefit to both the individual and their company will be learning how to better incorporate microbial process control into the product manufacturing lifecycle."

Register for "The Science of Pharmaceutical Microbiology Seminar."

The seminar will take place at the Hilton San Diego/Gaslamp at 401 K Street. Nelson Laboratories experts will present five different topics during the seminar, including:

Registration for this event will end on Friday, May 3, 2013. For any questions on registering groups or costs please contact marketing@nelsonlabs.com.

About Nelson Laboratories

Nelson Laboratories is a leading provider of full, life-cycle microbiology testing services. We are known for exceptional quality, but we look beyond the testing process and partner with you to achieve your long-term business goals. It's what we call The Science of Success. It's transparency in the testing process. It's approachable experts that guide you through ever-changing compliance requirements. It's helping you mitigate risk, be first to market, and succeed with your customers. Learn more at http://www.nelsonlabs.com.

PR Contact:

Ryan Oaks Snapp Conner PR 801-994-9625 ryan@snappconner.com

Read more:
Nelson Laboratories to Conduct Pharmaceutical Microbiology Seminar


  1. Microbiology